Health
Researchers identify aluminum hydroxide/TLR9 agonist as potential adjuvant to improve RBD-based COVID-19 vaccine efficacy – News-Medical.net
The study findings reveal that RBD-based vaccines adjuvanted with the formulation can induce strong anti-SARS-CoV-2 neutralizing immunity in young and aged mice….
A team of scientists from the United States has recently developed a formulation of toll-like receptor 9 (TLR9) agonist and aluminum hydroxide to increase the immunogenicity of spike receptor-binding domain (RBD) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
The study findings reveal that RBD-based vaccines adjuvanted with the formulation can induce strong anti-SARS-CoV-2 neutralizing immunity in young and aged mice. The study is currently available on the bioRxiv* preprint server.
…
-
Noosa News15 hours agoPill checking to resume in Queensland months after government axed funding
-
Business18 hours agoWhy Austal, Boss Energy, Harvey Norman, and NextDC shares are charging higher today
-
Business19 hours agoASX shares are expensive. Here’s why you should be buying anyway
-
Noosa News24 hours agoThe Full Trailer for Yorgos Lanthimos’ Emma Stone-Led CEO-Kidnapping Dark Comedy ‘Bugonia’ Is Here